Ustekinumab is a human immunoglobulin G1 (IgG1) kappa monoclonal antibody that blocks IL-12 and IL-23 and has been approved for the treatment of moderate to severe IBD and psoriatic arthritis [17]. The gene discussed is IL37; the disease is inflammatory bowel disease.